Why EXACT Sciences Corporation Jumped 13.2% in September
Shares of EXACT Sciences (NASDAQ: EXAS), a diagnostics company focused on colon cancer, rose more than 13% in September, according to data from S&P Global Market Intelligence. While it was a quiet month on the news front, an analyst at Leerink Partners released a bullish note to the investment community that helped to explain the rally.
Shareholders can thank Leerink Partners analyst Puneet Souda for putting out an upbeat report that featured Exact Sciences stock. Souda maintained his "Outperform" rating on the company's shares and also raised his price target by $5 to $50.
Souda stated that sales of the company's Cologuard test are poised to grow faster than the market is expecting as a result of increased support from the medical community.
Source: Fool.com
Exact Sciences Stock
Exact Sciences is currently one of the favorites of our community with 15 Buy predictions and no Sell predictions.
As a result the target price of 77 € shows a very positive potential of 82.75% compared to the current price of 42.14 € for Exact Sciences.
